Join our daily newsletter At The Bell to receive exclusive market insights
- Medlab Clinical’s (MDC) proprietary delivery platform NanoCell receives a Notice of Allowance by the United States Patent and Trademark Office
- Fees associated have been paid and Medlab is expecting to receive grant status with US patent numbers and expiry dates within the next four weeks
- NanoCelle is Medlab’s drug delivery nanotechnology that aims to overcome the current obstacles surrounding drug delivery
- It creates nano-sized water-soluble particles that enable optimised and standardised delivery of medicines
- Medlab ends the day 3.33 per cent in the green with shares trading at 15.5 cents
Medlab Clinical’s (MDC) proprietary delivery platform NanoCell has been issued a Notice of Allowance by the United States Patent and Trademark Office (USPTO).
Fees associated with the patent have been paid and Medlab is expecting to receive grant status with US patent numbers and expiry dates within the next four weeks.
NanoCelle is Medlab’s drug delivery nanotechnology that aims to overcome the current obstacles surrounding drug delivery.
It creates nano-sized water-soluble particles that enable optimised and standardised delivery of medicines.
NanoCelle’s global granted portfolio now covers the United States, Oceania, Asia, Europe and Canada.
CEO Sean Hall is pleased with the outcome after a long process.
“After approximately four years, this is an exceptional outcome. NanoCelle is a core asset of the company, and the United States represents the largest and last territory we were awaiting an outcome,” Dr Hall commented.
“Our expectation is that the patent expiry will follow the rest of the world and be set to 2036. Here and now, I am very happy to say NanoCell is protected on a global western scale.”
Medlab ended the day 3.33 per cent in the green with shares trading at 15.5 cents.
